Understand the source comparison
Intermittent Dosing vs Continuous Administration: What the Data Shows
Intermittent dosing. Administering SS-LUP-332 every 72–96 hours rather than daily. Produces higher peak receptor activation and more complete inter-dose recovery than continuous protocols. Research conducted at the University of California demonstrated that 72
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Intermittent dosing. Administering SS-LUP-332 every 72–96 hours rather than daily. Produces higher peak receptor activation and more complete inter-dose recovery than continuous protocols. Research conducted at the University of California demonstrated that 72-hour intervals allowed membrane-bound compound levels to drop below 20% occupancy before the next administration, creating a sawtooth activation pattern that traditional daily dosing cannot achieve.
- Here's what that looks like in practice: daily administration maintains receptor occupancy between 60–80% continuously, which sounds beneficial until you realise that sustained activation triggers compensatory downregulation within 10–14 days. By day 21, cellular response to the same dose has decreased by 30–40%. Not because the compound stopped working, but because the target cells adapted to constant signalling. Intermittent dosing at 72-hour intervals maintains peak occupancy above 85% immediately post-dose while allowing trough occupancy to fall below 15%, preserving receptor sensitivity across 8–12 week research windows.
- The data also reveals something most suppliers won't tell you: cumulative dosing matters more than cycle length with lupeol-derived peptides. A researcher administering 500mcg every 72 hours for 8 weeks achieves both higher peak responses and better maintained sensitivity than someone running 250mcg daily for 4 weeks followed by 4 weeks off. The total amount of compound administered is nearly identical. But the dosing architecture fundamentally changes the cellular response profile. Our team structures protocols around this principle when working with SS-LUP-332, prioritising intermittent high-amplitude signalling over sustained low-amplitude exposure.